It is well documented that DCs uptake and cross‐present tumor antigens to prime and activate cytotoxic CD8+ T lymphocytes for successful anticancer immune response,[38] therefore, reactivating DCs in TME is considered as an ideal therapeutic strategy against cancer. This evidence concerns the gene CD8A and cancer.